Trial Profile
A Phase I Study of Pazopanib in Combination With Either Erlotinib or Pemetrexed in Patients With Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Jun 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Erlotinib; Pemetrexed
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- Sponsors GlaxoSmithKline; GSK
- 07 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Sep 2009 Actual patient number (58) added as reported by ClinicalTrials.gov.
- 23 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.